Article Sidebar

pdf
Date Published: 05/05/2025
Abstract Views: 88
Views pdf: 48
DOI: https://doi.org/10.51298/vmj.v549i3.13921
Issue
Vol. 549 No. 3 (2025)
Section
Các bài báo
How to Cite
Nguyễn Thị Minh, H., & Vũ Thành, L. (2025). THE EFFICACY OF MOLECULAR TARGETED AGENT IN PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER AT 19-8 HOSPITAL MINISTRY OF PUBLIC SECURITY. Vietnam Medical Journal, 549(3). https://doi.org/10.51298/vmj.v549i3.13921

THE EFFICACY OF MOLECULAR TARGETED AGENT IN PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER AT 19-8 HOSPITAL MINISTRY OF PUBLIC SECURITY

Hải Nguyễn Thị Minh, Long Vũ Thành

Main Article Content

Abstract

Aims:  To evaluate the treatment outcomes in old patient with advanced non-small cell lung cancer treated by the molecular targeted agent. Patients and method: The patient diagnosed adenocarcinoma non small cell lung cancer stage IV, EGFR mutations (exon 19 deletion mutation or L858R) at 19-8  Hospital, from January 2022 to November 2024 treat with molecular targeted agent. Results: 30 patients with the overall response after 6 months rate were 73,3%, disease control rate were 86,7%. Patient with reduce and run out of symptom were 76,7%. The most side effects were rash 53,3%. Conclusion: Tyrosine kinase inhibitor was effective option to treatment first line in old patients with advanced non-small cell lung cancer patients with EGFR mutations positive.

Article Details

Keywords

non small cell lung cancer, tyrosine kinase inhibitor, Gefitinib, Erlotinib, Afatinib, Osimertinib

References

1. GLOBOCAN. International agency for research on cancer. 2018.
2. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. Mar 2012. 13(3):239-246.
3. Gao G, Ren S, Li A, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. Int J Cancer. Sep 1 2012. 131(5):E822-829..
4. Owonikoko TK, Ragin CC, Belani CP, et al. Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database. J Clin Oncol 25:5570-5577
5. Phạm Văn Phát (2020). Đánh giá kết quả hóa xạ trị đồng thời ung thư phổi không tế bào nhỏ giai đoạn III trên người cao tuổi tại Bệnh viện K, Luận văn thạc sĩ y học, Trường Đại Học Y Hà Nội.
6. Nguyễn Văn Cao, Nguyễn Thị Thái Hòa. Đánh giá kết quả điều trị Gefitinib bước 1 ung thư phổi không tế bào nhỏ giai đoạn IV có đột biến EGFR tại Bệnh viện K. Tạp chí ung thư học Việt Nam. 2019; 5: 224 – 229.
7. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGF, N Engl J Med. 2010;362: 2380 -2388.
8. YL Wu, LV Sequist, et al. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Clinical Lung Cancer.Volume 19, Issue 4, July 2018, Pages e465-e479
9. Y Inoue, N Inui, K Asada, M Karayama, et al (2015). Phase II study of erlotinib in elderly patients with non- small cell lung cancer harboring epidermal growth factor receptor mutations. Cancer Chemotherapy and Pharmacology volume 76, pages155–161
10. Anh, P. N., Việt, Đinh N., Việt, H. T. B., & Hạnh, C. X.. (2024). Đánh giá kết quả điều trị bước 1 bằng Osimertinib trong Ung thư phổi không tế bào nhỏ giai đoạn IV có đột biến EGFR tại Bệnh viện phổi Trung Ương giai đoạn 2019- 2022. Tạp Chí Y học Cộng đồng, 65.